GeneBioTech Co. Ltd Working Capital to Net Assets Ratio
GeneBioTech Co. Ltd working capital to net assets ratio. GeneBioTech Co. Ltd (086060) has a Working Capital to Net Assets ratio of 74.4% as of June 2026. Working capital of ₩41.86 Billion (current assets of ₩61.49 Billion minus current liabilities of ₩19.62 Billion) is measured against net assets of ₩56.25 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check tangible net worth ratio of GeneBioTech Co. Ltd to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of GeneBioTech Co. Ltd (2014–2025)
Working capital to net assets ratio of GeneBioTech Co. Ltd from 2014 to 2025. This chart shows how GeneBioTech Co. Ltd's Working Capital to Net Assets ratio has evolved across 12 annual periods from 2014 to 2025. As of June 2026, the ratio stands at 74.4%, reflecting working capital of ₩41.86 Billion against net assets of ₩56.25 Billion KRW. See 086060 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
GeneBioTech Co. Ltd Working Capital to Net Assets Ratio by Year (2014–2025)
GeneBioTech Co. Ltd working capital to net assets ratio by year from 2014 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for GeneBioTech Co. Ltd from 2014 to 2025, covering 12 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see GeneBioTech Co. Ltd total assets.
| Year | WC/NA Ratio | Working Capital (KRW) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 70.9% | ₩39.00 Billion | ₩55.00 Billion | ₩54.71 Billion | ₩15.71 Billion | ▼ -2.6 pp |
| 2024 | 73.5% | ₩37.47 Billion | ₩50.97 Billion | ₩55.84 Billion | ₩18.36 Billion | ▲ +1.5 pp |
| 2023 | 72.0% | ₩34.77 Billion | ₩48.30 Billion | ₩49.28 Billion | ₩14.51 Billion | ▲ +5.6 pp |
| 2022 | 66.4% | ₩30.35 Billion | ₩45.73 Billion | ₩46.27 Billion | ₩15.92 Billion | ▲ +2.6 pp |
| 2021 | 63.8% | ₩28.04 Billion | ₩43.95 Billion | ₩42.18 Billion | ₩14.14 Billion | ▼ -20.1 pp |
| 2020 | 83.9% | ₩37.79 Billion | ₩45.04 Billion | ₩45.47 Billion | ₩7.68 Billion | ▲ +11.6 pp |
| 2019 | 72.3% | ₩33.92 Billion | ₩46.93 Billion | ₩43.86 Billion | ₩9.94 Billion | ▲ +1.2 pp |
| 2018 | 71.1% | ₩34.10 Billion | ₩47.96 Billion | ₩48.13 Billion | ₩14.03 Billion | ▲ +24.8 pp |
| 2017 | 46.2% | ₩18.73 Billion | ₩40.49 Billion | ₩30.97 Billion | ₩12.25 Billion | ▲ +4.3 pp |
| 2016 | 42.0% | ₩16.37 Billion | ₩39.02 Billion | ₩27.91 Billion | ₩11.53 Billion | ▼ -12.9 pp |
| 2015 | 54.8% | ₩15.80 Billion | ₩28.84 Billion | ₩26.66 Billion | ₩10.85 Billion | ▲ +5.1 pp |
| 2014 | 49.7% | ₩11.64 Billion | ₩23.42 Billion | ₩24.65 Billion | ₩13.01 Billion | — |